(ALKS) Alkermes - Overview
Exchange: NASDAQ •
Country: Ireland •
Currency: USD •
Type: Common Stock •
ISIN: IE00B56GVS15
Stock: Schizophrenia, Bipolar, Alcohol, Opioid, Injectable
Total Rating 50
Risk 86
Buy Signal 0.46
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 39.0% |
| Relative Tail Risk | -9.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | -0.31 |
| Character TTM | |
|---|---|
| Beta | 0.618 |
| Beta Downside | 0.763 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.58% |
| CAGR/Max DD | 0.28 |
Description: ALKS Alkermes January 10, 2026
Alkermes plc (NASDAQ: ALKS) is a Dublin-based biopharmaceutical firm that discovers, develops, and markets drugs for unmet needs in the United States, Ireland, and other markets. Its commercial portfolio includes ARISTADA (a long-acting injectable for schizophrenia), ARISTADA INITIO, VIVITROL (for alcohol dependence and opioid-use prevention), and the oral antipsychotic LYBALVI, while its pipeline targets neurological disorders such as major depressive disorder and Parkinson’s disease. The company also licenses proprietary drug-delivery technologies and maintains strategic collaborations with Janssen Pharmaceutica.
Key recent metrics: FY 2023 revenue reached approximately $1.1 billion, with ARISTADA contributing roughly 70 % of sales; the firm reported a cash runway of about $500 million, supporting ongoing Phase 2/3 trials of ALKS 4230 (a novel oral antidepressant) and ALKS 5461 (a rapid-acting antipsychotic). Sector-wide, the CNS biopharma market is expanding at a CAGR of ~6 % driven by aging demographics, increasing mental-health spending, and FDA incentives for long-acting injectable therapies.
For a deeper, data-driven valuation, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 338.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 6.45 > 1.0 |
| NWC/Revenue: 83.30% < 20% (prev 73.78%; Δ 9.52% < -1%) |
| CFO/TA 0.23 > 3% & CFO 541.1m > Net Income 338.8m |
| Net Debt (-544.9m) to EBITDA (435.8m): -1.25 < 3 |
| Current Ratio: 3.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (168.5m) vs 12m ago 0.89% < -2% |
| Gross Margin: 86.04% > 18% (prev 0.83%; Δ 8521 % > 0.5%) |
| Asset Turnover: 67.84% > 50% (prev 69.83%; Δ -1.99% > 0%) |
| Interest Coverage Ratio: 87.27 > 6 (EBITDA TTM 435.8m / Interest Expense TTM 4.65m) |
Altman Z'' 2.31
| A: 0.54 (Total Current Assets 1.74b - Total Current Liabilities 474.4m) / Total Assets 2.33b |
| B: -0.34 (Retained Earnings -784.1m / Total Assets 2.33b) |
| C: 0.18 (EBIT TTM 405.6m / Avg Total Assets 2.24b) |
| D: -1.31 (Book Value of Equity -783.4m / Total Liabilities 596.1m) |
| Altman-Z'' Score: 2.31 = BBB |
Beneish M -3.26
| DSRI: 0.95 (Receivables 355.1m/370.2m, Revenue 1.52b/1.51b) |
| GMI: 0.97 (GM 86.04% / 83.17%) |
| AQI: 0.87 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.01 (Revenue 1.52b / 1.51b) |
| TATA: -0.09 (NI 338.8m - CFO 541.1m) / TA 2.33b) |
| Beneish M-Score: -3.26 (Cap -4..+1) = AA |
What is the price of ALKS shares?
As of February 09, 2026, the stock is trading at USD 34.91 with a total of 1,938,867 shares traded.
Over the past week, the price has changed by -0.14%, over one month by +17.94%, over three months by +6.92% and over the past year by +11.78%.
Over the past week, the price has changed by -0.14%, over one month by +17.94%, over three months by +6.92% and over the past year by +11.78%.
Is ALKS a buy, sell or hold?
Alkermes has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy ALKS.
- StrongBuy: 8
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALKS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.8 | 25.5% |
| Analysts Target Price | 43.8 | 25.5% |
| ValueRay Target Price | 35.9 | 2.9% |
ALKS Fundamental Data Overview February 05, 2026
P/E Trailing = 17.1493
P/E Forward = 21.5983
P/S = 3.7412
P/B = 3.2282
P/EG = -1057.29
Revenue TTM = 1.52b USD
EBIT TTM = 405.6m USD
EBITDA TTM = 435.8m USD
Long Term Debt = 71.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.63m USD (from shortTermDebt, last quarter)
Debt = 71.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -544.9m USD (from netDebt column, last quarter)
Enterprise Value = 4.65b USD (5.69b + Debt 71.6m - CCE 1.11b)
Interest Coverage Ratio = 87.27 (Ebit TTM 405.6m / Interest Expense TTM 4.65m)
EV/FCF = 9.48x (Enterprise Value 4.65b / FCF TTM 490.9m)
FCF Yield = 10.55% (FCF TTM 490.9m / Enterprise Value 4.65b)
FCF Margin = 32.27% (FCF TTM 490.9m / Revenue TTM 1.52b)
Net Margin = 22.27% (Net Income TTM 338.8m / Revenue TTM 1.52b)
Gross Margin = 86.04% ((Revenue TTM 1.52b - Cost of Revenue TTM 212.4m) / Revenue TTM)
Gross Margin QoQ = 86.91% (prev 87.34%)
Tobins Q-Ratio = 2.00 (Enterprise Value 4.65b / Total Assets 2.33b)
Interest Expense / Debt = 6.49% (Interest Expense 4.65m / Debt 71.6m)
Taxrate = 17.85% (18.0m / 100.7m)
NOPAT = 333.2m (EBIT 405.6m * (1 - 17.85%))
Current Ratio = 3.67 (Total Current Assets 1.74b / Total Current Liabilities 474.4m)
Debt / Equity = 0.04 (Debt 71.6m / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = -1.25 (Net Debt -544.9m / EBITDA 435.8m)
Debt / FCF = -1.11 (Net Debt -544.9m / FCF TTM 490.9m)
Total Stockholder Equity = 1.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.11% (Net Income 338.8m / Total Assets 2.33b)
RoE = 21.40% (Net Income TTM 338.8m / Total Stockholder Equity 1.58b)
RoCE = 24.50% (EBIT 405.6m / Capital Employed (Equity 1.58b + L.T.Debt 71.6m))
RoIC = 21.04% (NOPAT 333.2m / Invested Capital 1.58b)
WACC = 8.15% (E(5.69b)/V(5.76b) * Re(8.19%) + D(71.6m)/V(5.76b) * Rd(6.49%) * (1-Tc(0.18)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.48%
[DCF Debug] Terminal Value 80.56% ; FCFF base≈420.6m ; Y1≈511.5m ; Y5≈842.9m
Fair Price DCF = 87.16 (EV 13.85b - Net Debt -544.9m = Equity 14.39b / Shares 165.1m; r=8.15% [WACC]; 5y FCF grow 23.10% → 2.90% )
EPS Correlation: 45.35 | EPS CAGR: -33.78% | SUE: -1.93 | # QB: 0
Revenue Correlation: 48.19 | Revenue CAGR: 5.33% | SUE: 1.66 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.28 | Chg30d=-0.100 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=2.05 | Chg30d=-0.111 | Revisions Net=+0 | Growth EPS=+3.0% | Growth Revenue=+23.9%
P/E Forward = 21.5983
P/S = 3.7412
P/B = 3.2282
P/EG = -1057.29
Revenue TTM = 1.52b USD
EBIT TTM = 405.6m USD
EBITDA TTM = 435.8m USD
Long Term Debt = 71.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.63m USD (from shortTermDebt, last quarter)
Debt = 71.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -544.9m USD (from netDebt column, last quarter)
Enterprise Value = 4.65b USD (5.69b + Debt 71.6m - CCE 1.11b)
Interest Coverage Ratio = 87.27 (Ebit TTM 405.6m / Interest Expense TTM 4.65m)
EV/FCF = 9.48x (Enterprise Value 4.65b / FCF TTM 490.9m)
FCF Yield = 10.55% (FCF TTM 490.9m / Enterprise Value 4.65b)
FCF Margin = 32.27% (FCF TTM 490.9m / Revenue TTM 1.52b)
Net Margin = 22.27% (Net Income TTM 338.8m / Revenue TTM 1.52b)
Gross Margin = 86.04% ((Revenue TTM 1.52b - Cost of Revenue TTM 212.4m) / Revenue TTM)
Gross Margin QoQ = 86.91% (prev 87.34%)
Tobins Q-Ratio = 2.00 (Enterprise Value 4.65b / Total Assets 2.33b)
Interest Expense / Debt = 6.49% (Interest Expense 4.65m / Debt 71.6m)
Taxrate = 17.85% (18.0m / 100.7m)
NOPAT = 333.2m (EBIT 405.6m * (1 - 17.85%))
Current Ratio = 3.67 (Total Current Assets 1.74b / Total Current Liabilities 474.4m)
Debt / Equity = 0.04 (Debt 71.6m / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = -1.25 (Net Debt -544.9m / EBITDA 435.8m)
Debt / FCF = -1.11 (Net Debt -544.9m / FCF TTM 490.9m)
Total Stockholder Equity = 1.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.11% (Net Income 338.8m / Total Assets 2.33b)
RoE = 21.40% (Net Income TTM 338.8m / Total Stockholder Equity 1.58b)
RoCE = 24.50% (EBIT 405.6m / Capital Employed (Equity 1.58b + L.T.Debt 71.6m))
RoIC = 21.04% (NOPAT 333.2m / Invested Capital 1.58b)
WACC = 8.15% (E(5.69b)/V(5.76b) * Re(8.19%) + D(71.6m)/V(5.76b) * Rd(6.49%) * (1-Tc(0.18)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.48%
[DCF Debug] Terminal Value 80.56% ; FCFF base≈420.6m ; Y1≈511.5m ; Y5≈842.9m
Fair Price DCF = 87.16 (EV 13.85b - Net Debt -544.9m = Equity 14.39b / Shares 165.1m; r=8.15% [WACC]; 5y FCF grow 23.10% → 2.90% )
EPS Correlation: 45.35 | EPS CAGR: -33.78% | SUE: -1.93 | # QB: 0
Revenue Correlation: 48.19 | Revenue CAGR: 5.33% | SUE: 1.66 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.28 | Chg30d=-0.100 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=2.05 | Chg30d=-0.111 | Revisions Net=+0 | Growth EPS=+3.0% | Growth Revenue=+23.9%